Cystic Fibrosis is Proof of Principle for Drug Development for Rare Diseases, says NIH Director on Minnesota Public Radio
| 1 min read

New drugs in development for cystic fibrosis are extremely encouraging and could be "really quite powerful," says Francis S. Collins, M.D., Ph.D, in an interview with "All Things Considered" of Minnesota Public Radio.
The new director of the National Institutes of Health, Collins says that cystic fibrosis has created a "proof of principle" demonstrating that new therapies can be created for rare and neglected diseases. He plans to tackle this area of drug development as one of his top priorities at NIH.
Collins notes a promising outlook for those with CF: "There has been a steady and very gratifying increase in survival for this disease, going back over the last 50 years. Many individuals with CF are living into their 40s, 50s or even 60s."
Collins was interviewed during the North American Cystic Fibrosis Conference last week.

Share this article
About the CF Foundation | Research | Drug Pipeline
Recent news
CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug
News | 2 min read
CF Foundation Advocates to Protect Needs of People With CF in Post-Pandemic Medicaid Redeterminations
News | 5 min read
FDA Approves Kalydeco for Infants as Young as 1 Month
News | 4 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.